titlesubmit dateissue date
Now showing items 1-4 of 4
Critically short telomeres and toxicity of chemotherapy in early breast cancer
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial.
In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer
Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer